

## Non-clinical study of OM202-001 from NSDC platform for the treatment of Autoimmune diseases



IMMUNOLOGY	Preclinical
Product Type	Small molecules
Indication	IBD (Ulcerative Colitis, Crohn's Disease)
Target	JAK, Nitric Oxide
MoA(Mechanism of Action)	Nitric Oxide sensitive release of active JAK inhibitor.
Competitiveness	<ul style="list-style-type: none"> <li>• Synergistic effects &amp; reduced toxicity of payload(Tofacitinib, JAK inhibitor) such as ADC (Antibody-Drug-Conjugate).</li> <li>• Simple CMC due to all small molecules unlike ADC.</li> <li>• Possible Oral Administration.</li> </ul>
Development Stage	Preclinical
Route of Administration	Oral administration

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*